

**Table S1. List of MAN-associated proteins modified in disease.**

| Disease            | Protein involved | Modifications                                                                       | Altered MAN                          | Refs.                                         |
|--------------------|------------------|-------------------------------------------------------------------------------------|--------------------------------------|-----------------------------------------------|
| PD                 | Parkin           | LOF mutation leading to decrease in DRP-1 degradation                               | Mitochondrial fission                | (Wang et al., 2011; Yu et al., 2011)          |
|                    | Miro1            | LOF mutation leading to impaired calcium homeostasis and increased mitophagy        | Calcium signaling                    | (Grossmann et al., 2020)                      |
|                    | GBA1             | LOF mutation abnormally prolonging lysosomal-mitochondrial tethering                | Mitochondrial fission                | (Kim et al., 2021)                            |
| Cancer             | DRP-1            | Increased activity leading to cell proliferation and migration                      | Mitochondrial fission                | (Kashatus, 2018)                              |
| CMT-2A             | MFN2             | Mutation promoting mitochondrial hyperfusion by increased DRP-1 degradation         | Mitochondrial fission                | (Cartoni and Martinou, 2009)                  |
|                    | DRP-1            | Increased R364W-MFN2-mediated ubiquitination leading to mitochondrial hyperfusion   | Mitochondrial fission                | (Das et al., 2021)                            |
| ALS                | Sig-1R           | LOF mutation leading to impaired binding to IP3R and mitochondrial dysfunction      | Calcium signaling                    | (Al-Saif et al., 2011; Watanabe et al., 2016) |
| NASH and cancer    | MFN2             | Low expression leading to impaired PS transfer                                      | Lipid exchange                       | (Hernández-Alvarez et al., 2019)              |
| GM1-gangliosidosis | GLB1             | LOF mutation leading to lysosomal dysfunction and neurodegeneration                 | Calcium signaling and Lipid exchange | (Sano et al., 2009)                           |
| NPC                | NPC1             | LOF mutation leading to accumulation of cholesterol at lysosomes causing cell death | Lipid exchange                       | (Wheeler and Sillence, 2020)                  |

Abbreviations: amyotrophic lateral sclerosis (ALS); Charcot-Marie-Tooth disease type2A (CMT-2A); dynamin related protein 1 (DRP-1);  $\beta$ -glucocerebrosidase (GBA1);  $\beta$ -galactosidase (GLB1); Loss-of-function (LOF); mitofusin 2 (MFN2); Non-alcoholic steatohepatitis (NASH); Niemann-Pick type C (NPC); NPC intracellular cholesterol transporter 1 (NPC1); Parkinson's disease (PD); phosphatidylserine (PS); sigma-1R (Sig-1R).

## References:

- Al-Saif, A., Al-Mohanna, F. and Bohlega, S.** (2011). A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. *Annals of Neurology* **70**, 913–919.
- Cartoni, R. and Martinou, J.-C.** (2009). Role of mitofusin 2 mutations in the physiopathology of Charcot–Marie–Tooth disease type 2A. *Experimental Neurology* **218**, 268–273.
- Das, R., Kamal, I. M., Das, S., Chakrabarti, S. and Chakrabarti, O.** (2021). MITOL-mediated DRP1 ubiquitylation and degradation promotes mitochondrial hyperfusion in CMT2A-linked MFN2 mutant. *Journal of Cell Science* jcs.257808.
- Grossmann, D., Berenguer-Escuder, C., Chemla, A., Arena, G. and Krüger, R.** (2020). The Emerging Role of RHOT1/Miro1 in the Pathogenesis of Parkinson's Disease. *Front Neurol* **11**, 587.
- Hernández-Alvarez, M. I., Sebastián, D., Vives, S., Ivanova, S., Bartoccioni, P., Kakimoto, P., Plana, N., Veiga, S. R., Hernández, V., Vasconcelos, N., et al.** (2019). Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. *Cell* **177**, 881–895.e17.
- Kashatus, D. F.** (2018). The Regulation of Tumor Cell Physiology by Mitochondrial Dynamics. *Biochem Biophys Res Commun* **500**, 9–16.
- Kim, S., Wong, Y. C., Gao, F. and Krainc, D.** (2021). Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease. *Nat Commun* **12**, 1807.
- Sano, R., Annunziata, I., Patterson, A., Moshiach, S., Gomero, E., Opferman, J., Forte, M. and d'Azzo, A.** (2009). GM1-Ganglioside Accumulation at the Mitochondria-Associated ER Membranes Links ER Stress to Ca<sup>2+</sup>-Dependent Mitochondrial Apoptosis. *Molecular Cell* **36**, 500–511.
- Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y. L., Selkoe, D., Rice, S., Steen, J., Lavoie, M. J. and Schwarz, T. L.** (2011). PINK1 and Parkin target miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell* **147**, 893–906.
- Watanabe, S., Ilieva, H., Tamada, H., Nomura, H., Komine, O., Endo, F., Jin, S., Mancias, P., Kiyama, H. and Yamanaka, K.** (2016). Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1 - and SOD 1 -linked ALS . *EMBO Molecular Medicine* **8**, 1421–1437.
- Wheeler, S. and Sillence, D. J.** (2020). Niemann–Pick type C disease: cellular pathology and pharmacotherapy. *Journal of Neurochemistry* **153**, 674–692.
- Yu, W., Sun, Y., Guo, S. and Lu, B.** (2011). The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. *Human Molecular Genetics* **20**, 3227–3240.